Progression of targeted therapy in advanced cholangiocarcinoma.
It is necessary to establish an effective therapy to improve the survival of patients with advanced cholangiocarcinoma (CCA). Recently, with the development of pathology research in CCA, a lot of special bio-markers such as EGFR, VEGF, HER2, and MEK et al. could be over expression or mutations in CCA patients. According to their changes, combinations of targeted therapy plus chemotherapy are now recognized as effective therapies for advanced CCA. The aim of this paper is to analyze recent promising studies about targeted therapy alone or combination with each other or with chemotherapies.
1 Oncology Department, Beijing Hospital of the Ministry of Health, Beijing 100038, China ; 2 Oncology Department, Chinese PLA General hospital, Beijing 100853, China.
Yingying
Y
Huang
1 Oncology Department, Beijing Hospital of the Ministry of Health, Beijing 100038, China ; 2 Oncology Department, Chinese PLA General hospital, Beijing 100853, China.
Xiaomei
X
Li
1 Oncology Department, Beijing Hospital of the Ministry of Health, Beijing 100038, China ; 2 Oncology Department, Chinese PLA General hospital, Beijing 100853, China.
Yunbo
Y
Zhao
Cholangiocarcinoma (CCA); advanced tumor; combined therapy; molecular targeted therapy; tumor therapy